Evidence map›Paper›PMID 27779915›Full record

ArticleEndocrinology2016

GPR119, a Major Enteroendocrine Sensor of Dietary Triglyceride Metabolites Coacting in Synergy With FFA1 (GPR40).

Jeppe H Ekberg, Maria Hauge, Line V Kristensen, Andreas N Madsen, Maja S Engelstoft, Anna-Sofie Husted, Rasmus Sichlau, Kristoffer L Egerod, Pascal Timshel, Timothy J Kowalski and 6 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04432090 (A Randomized, Placebo-controlled, Double-blinded Cross-over Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus), which is not on this map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04432090 phase2completednot on this mapstarted 2021, after this paper: background citation

A Randomized, Placebo-controlled, Double-blinded Cross-over Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus

TypeinterventionalSponsorAdventHealth Translational Research InstituteRan2021 to 2023Enrolled110ConditionsDiabetes Mellitus, Type 1ArmsPlacebo, Study Medication (MBX-2982), No medication for this group
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 100 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. L-cell-specificActa pharmaceutica Sinica. B · 2026
    Article
  6. Review
  7. Functional characteristics of a pig 2D intestinal organoid model as anJournal of animal science and technology · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Cellular mechanisms of incretin hormone secretion.Journal of molecular endocrinology · 2024
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Jeppe H EkbergNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Maria HaugeNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Line V KristensenNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Andreas N MadsenNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Maja S EngelstoftNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Anna-Sofie HustedNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Rasmus SichlauNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Kristoffer L EgerodNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Pascal TimshelNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Timothy J KowalskiNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Fiona M GribbleNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Frank ReimanNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Harald S HansenNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Andrew D HowardNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Birgitte HolstNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Thue W SchwartzNNF Center for Basic Metabolic Research (J.H.E., M.H., L.V.K., A.N.M., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Section for Metabolic Receptology; Laboratory for Molecular Pharmacology (J.H.E., M.H., L.V.K., M.S.E., A.-S.H., R.S., K.L.E., B.H., T.W.S.), Department of Neuroscience and Pharmacology; and Danish Diabetes Academy (M.S.E.), 5000 Odense, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research (P.T.), Section for Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; Merck Research Laboratories (T.J.K., A.D.H.), Kenilworth, New Jersey 07033; Cambridge Institute for Medical Research and MRC Metabolic Diseases Unit (F.M.G., F.R.), University of Cambridge, Cambridge, CB20QQ United Kingdom; Department of Drug Design and Pharmacology (H.S.H.), University of Copenhagen, DK-2100 Copenhagen, Denmark.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USMRC Epidemiology Unit · GBUniversity of Copenhagen · DKDanish Diabetes Academy · DK

Funding

Medical Research Council MC_UU_12012/3Wellcome Trust 088357
6 · The paper itself

Abstract

Triglycerides (TGs) are among the most efficacious stimulators of incretin secretion; however, the relative importance of FFA1 (G Protein-coupled Receptor [GPR] 40), FFA4 (GPR120), and GPR119, which all recognize TG metabolites, ie, long-chain fatty acid and 2-monoacylglycerol, respectively, is still unclear. Here, we find all 3 receptors to be highly expressed and highly enriched in fluorescence-activated cell sorting-purified GLP-1 and GIP cells isolated from transgenic reporter mice. In vivo, the TG-induced increase in plasma GIP was significantly reduced in FFA1-deficient mice (to 34%, mean of 4 experiments each with 8-10 animals), in GPR119-deficient mice (to 24%) and in FFA1/FFA4 double deficient mice (to 15%) but not in FFA4-deficient mice. The TG-induced increase in plasma GLP-1 was only significantly reduced in the GPR119-deficient and the FFA1/FFA4 double deficient mice, but not in the FFA1, and FFA4-deficient mice. In mouse colonic crypt cultures the synthetic FFA1 agonists, TAK-875 stimulated GLP-1 secretion to a similar extent as the prototype GLP-1 secretagogue neuromedin C; this, however, only corresponded to approximately half the maximal efficiency of the GPR119 agonist AR231453, whereas the GPR120 agonist Metabolex-209 had no effect. Importantly, when the FFA1 agonist was administered on top of appropriately low doses of the GPR119 agonist, a clear synergistic, ie, more than additive, effect was observed. It is concluded that the 2-monoacylglycerol receptor GPR119 is at least as important as the long-chain fatty acid receptor FFA1 in mediating the TG-induced secretion of incretins and that the 2 receptors act in synergy, whereas FFA4 plays a minor if any role.

Indexed as

AnimalsBenzofuransBombesinColonDietary FatsGlucagon-Like Peptide 1MiceMice, KnockoutPeptide FragmentsReceptors, G-Protein-CoupledSulfonesTriglyceridesBenzofuransBombesinDietary FatsFfar1 protein, mouseFFAR4 protein, mouseGlucagon-Like Peptide 1Gpr119 protein, mouseneuromedin CPeptide FragmentsReceptors, G-Protein-CoupledSulfonesTAK-875Triglycerides

Identifiers

PMID27779915
PMCPMC7212052
OpenAlexW2539336285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.